Key findings from the GATEWAY study include the following:
At study week 20, administration of 200 mg or 300 mg ARO-ANG3 on day 1 and day 84 led to the following changes:
Mean reductions in LDL-C (Martin-Hopkins) of 48.1% and 44.0%, respectively
These reductions were achieved on top of continued standard of care, including statins, ezetimibe, PCSK9 inhibitors, and apheresis
Mean reductions in ApoB of 39.2% and 34.5%, respectively
Mean reductions in ANGPTL3 of 82.7% and 80.1%, respectively
AN(G)PTL3 inhibition with ARO-ANG3 also reduced HDL-C, non-HDL-C, and triglycerides, consistent with published human genetic data
van Holden.